Figure 4.

Anti-tumour activity of conatumumab in vivo using the sensitive Rh1 EWS cells. (A) Rh1, a sensitive EWS cell line, was inoculated intramuscularly into SCID mice. After 4 weeks, mice were randomised treated with conatumumab or placebo weekly for a total of 12 weeks. Tumour incidence was recorded and shown for both control and conatumumab arms. P-value was determined with Fisher's exact test. (B) Kaplan–Meier survival analysis of the mice with Rh1 xenograft to determine Log-Rank P-value of conatumumab treatment and control.